(Q37566053)

21 August 2017

1 reference

title

Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians (English)

1 reference

21 August 2017

George L Bakris

1

1 reference

21 August 2017

Louis Kuritzky

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

21 August 2017

published in

Postgraduate Medicine

1 reference

21 August 2017

volume

121

1 reference

21 August 2017

issue

4

1 reference

21 August 2017

page(s)

51-60

1 reference

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Time to abandon microalbuminuria?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Prevalence of chronic kidney disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Prevalence and determinants of microalbuminuria among diabetic patients in the United Arab Emirates

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Independent components of chronic kidney disease as a cardiovascular risk state: results from the Kidney Early Evaluation Program (KEEP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Higher levels of albuminuria within the normal range predict incident hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Early detection of chronic kidney disease: results of the PolNef study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Albuminuria, but not estimated glomerular filtration rate, is associated with maladaptive arterial remodeling: the Hoorn Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Microalbuminuria is a negative correlate for cognitive function in older adults with peripheral arterial disease: results from the U.S. National Health and Nutrition Examination Survey 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Disease-dependent mechanisms of albuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

The role of the kidneys in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Albuminuria reflects widespread vascular damage. The Steno hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with albuminuria in hypertensive African Americans: the HyperGEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

A comparative evaluation of various methods for microalbuminuria screening

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Standards of medical care in diabetes--2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

The assessment and management of albuminuria in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

A study of the prevalence of significant increases in serum creatinine following angiotension-converting enzyme inhibitor administration

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Efficacy and safety of benazepril for advanced chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Aliskiren combined with losartan in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Renin-angiotensin blockade and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Microalbuminuria and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Cross-Classification of Microalbuminuria and Reduced Glomerular Filtration Rate

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2009.07.2031

21 January 2018

Identifiers

DOI

10.3810/PGM.2009.07.2031

1 reference

21 August 2017

1 reference